Inhibition of inducible nitric oxide synthase exacerbates chronic cerebral toxoplasmosis in Toxoplasma gondii-susceptible C57BL/6 mice but does not reactivate the latent disease in T. gondii-resistant BALB/c mice.
Infection of C57BL/6 mice with Toxoplasma gondii leads to progressive and ultimately fatal chronic Toxoplasma encephalitis (TE). Genetic deletion or inhibition of inducible nitric oxide synthase (iNOS) from the beginning of infection increased the number of T. gondii cysts in the brain and markedly reduced the time-to-death in this mouse strain. In the present study, we addressed whether iNOS also contributes to the control of intracerebral parasites in a clinically stable latent infection that develops in T. gondii-resistant BALB/c mice after resolution of the acute phase of TE. iNOS was expressed in the inflammatory cerebral infiltrates of latently infected BALB/c mice, but the number of iNOS+ cells was significantly lower than in the brains of chronically infected T. gondii-susceptible C57BL/6 mice. In BALB/c mice with latent TE (> 30 days of infection), treatment with the iNOS inhibitors L-N6-iminoethyl-lysine or L-nitroarginine-methylester for < or = 40 days did not result in an increase of the intracerebral parasitic load and a reactivation of the disease, despite the presence of iNOS-suppressive inhibitor levels in the brain. However, L-nitroarginine-methylester treatment had remarkably toxic effects and induced a severe wasting syndrome with high mortality. In contrast to BALB/c mice, L-N6-iminoethyl-lysine treatment rapidly exacerbated the already established chronic TE of C57BL/6 mice. Thus, the containment of latent toxoplasms in T. gondii-resistant BALB/c mice is independent of iNOS, whereas the temporary control of intracerebral parasites in T. gondii-susceptible C57BL/6 mice with chronic TE requires iNOS activity.
Schlüter
D
D
Institut für Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Mannheim, Universität Heidelberg, Germany.
Deckert-Schlüter
M
M
Lorenz
E
E
Meyer
T
T
Röllinghoff
M
M
Bogdan
C
C
D000284:Administration, Oral; D000818:Animals; D001921:Brain / Q000201:enzymology / Q000378:metabolism; D002908:Chronic Disease; D004660:Encephalitis / Q000201:enzymology / Q000209:etiology / Q000469:parasitology; D004790:Enzyme Induction / Q000235:genetics / Q000276:immunology; D004791:Enzyme Inhibitors / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease / Q000201:enzymology / Q000276:immunology / Q000469:parasitology*; D007113:Immunity, Innate; D007700:Kinetics; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D052247:Nitric Oxide Synthase Type II; D013045:Species Specificity; D014122:Toxoplasma / Q000254:growth & development / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000201:enzymology* / Q000235:genetics / Q000276:immunology / Q000469:parasitology; D016781:Toxoplasmosis, Cerebral / Q000201:enzymology* / Q000235:genetics / Q000276:immunology / Q000469:parasitology
D004791:Enzyme Inhibitors; C090663:N(6)-(1-iminoethyl)lysine; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D008239:Lysine; D019331:NG-Nitroarginine Methyl Ester